Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Canagliflozin→

Canagliflozin Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
842133-18-0
Molecular formula
C24H25FO5S
Molecular weight
444.52 g/mol
Drug class
Selective sodium-glucose cotransporter 2 (SGLT2) inhibitororal antihyperglycaemic
Mechanism of action
Inhibits SGLT2 in the proximal renal tubule, reducing reabsorption of filtered glucose and increasing urinary glucose excretion. This lowers blood glucose and also affects intraglomerular haemodynamics and renal/cardiovascular risk pathways.
Indications / reported uses
  • Glycaemic control in adults with type 2 diabetes mellitus as an adjunct to diet and exercise
  • Reduction of major adverse cardiovascular events in adults with type 2 diabetes and established cardiovascular disease
  • Reduction of risk of end-stage kidney disease, doubling of serum creatinine, cardiovascular death and hospitalisation for heart failure in adults with type 2 diabetes and diabetic nephropathy with albuminuria, under the applicable US label

Sources: US DailyMed — INVOKANA (canagliflozin) · FDA prescribing information · FDA product information

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Canagliflozin Environmental Risk Assessment (ERA) (the Canagliflozin ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.